Nasus Pharma Ltd.
Nasus Pharma Ltd. operates as a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. The company offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency… Read more
Nasus Pharma Ltd. (NSRX) - Net Assets
Latest net assets as of December 2024: $-3.21 Million USD
Based on the latest financial reports, Nasus Pharma Ltd. (NSRX) has net assets worth $-3.21 Million USD as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($717.00K) and total liabilities ($3.93 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-3.21 Million |
| % of Total Assets | -447.98% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Nasus Pharma Ltd. - Net Assets Trend (2022–2024)
This chart illustrates how Nasus Pharma Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Nasus Pharma Ltd. (2022–2024)
The table below shows the annual net assets of Nasus Pharma Ltd. from 2022 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-3.21 Million | +15.41% |
| 2023-12-31 | $-3.80 Million | -36.34% |
| 2022-12-31 | $-2.79 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Nasus Pharma Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 258300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $9.45 Million | % |
| Total Equity | $-3.21 Million | 100.00% |
Nasus Pharma Ltd. Competitors by Market Cap
The table below lists competitors of Nasus Pharma Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Micropac Industries Inc
PINK:MPAD
|
$12.06 Million |
|
Cengild Medical Berhad
KLSE:0243
|
$12.07 Million |
|
Aqua Metals Inc
NASDAQ:AQMS
|
$12.07 Million |
|
Caravelle International Group Ordinary Shares
NASDAQ:CACO
|
$12.08 Million |
|
Tugcelik Aluminyum ve Metal
IS:TUCLK
|
$12.06 Million |
|
Telcon Inc
KQ:200230
|
$12.06 Million |
|
Nusa Konstruksi Enjiniring Tbk
JK:DGIK
|
$12.06 Million |
|
White Pearl Technology Group B
ST:WPTG-B
|
$12.05 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nasus Pharma Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -3,797,000 to -3,212,000, a change of 585,000.
- Net loss of 1,532,000 reduced equity.
- Other factors increased equity by 2,117,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.53 Million | -47.7% |
| Other Changes | $2.12 Million | +65.91% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Nasus Pharma Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | $-0.31 | $3.10 | x |
| 2023-12-31 | $-0.42 | $3.10 | x |
| 2024-12-31 | $-0.35 | $3.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nasus Pharma Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.43 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-671.30K |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.21 Million |
Industry Comparison
This section compares Nasus Pharma Ltd.'s net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $308,328,125,500
- Average return on equity (ROE) among peers: 18.93%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nasus Pharma Ltd. (NSRX) | $-3.21 Million | 0.00% | N/A | $12.06 Million |
| AbbVie Inc (ABBV) | $13.10 Billion | 35.24% | 10.50x | $390.88 Billion |
| Astellas Pharma Inc (ALPMF) | $1.06 Trillion | 7.80% | 0.36x | $16.93 Billion |
| Amgen Inc (AMGN) | $20.39 Billion | 20.58% | 0.79x | $196.91 Billion |
| Amarin Corporation PLC (AMRN) | $28.90 Million | 14.19% | 0.23x | $303.32 Million |
| AstraZeneca PLC (AZN) | $48.72 Billion | 21.05% | 1.34x | $296.35 Billion |
| Bayer AG (BAYZF) | $31.90 Billion | 14.21% | 1.58x | $21.61 Billion |
| Biogen Inc (BIIB) | $325.20 Million | 9.96% | 0.10x | $26.81 Billion |
| Bristol-Myers Squibb Company (BMY) | $5.08 Billion | 14.69% | 0.67x | $121.36 Billion |
| Chugai Pharmaceutical Co. Ltd (CHGCF) | $1.90 Trillion | 20.37% | 0.16x | $28.30 Billion |
| Cosmo Pharmaceuticals N.V (CMOPF) | $220.16 Million | 31.22% | 0.10x | $529.97 Million |